Personalized Low-Dose Radiation for Newly Diagnosed Lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding personalized, low-dose radiation therapy to standard chemotherapy improves outcomes for newly diagnosed diffuse large B-cell lymphoma (DLBCL). The radiation plan is tailored based on how well your cancer responds to chemotherapy early on.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 19 years old and have been newly diagnosed with diffuse large B-cell lymphoma (DLBCL) or a related large B-cell lymphoma confirmed by biopsy
- You are eligible to receive 6 cycles of combination chemotherapy called R-chemoimmunotherapy (or may have already started 1 cycle)
- You have measurable disease on imaging: a lymph node larger than 1.5 cm or a tumor outside lymph nodes larger than 1 cm
- You have a stored tissue sample from your tumor biopsy that can be used to create a personalized test to measure your cancer's response
- You have not already received 2 or more cycles of the planned chemotherapy for this cancer
- You are not pregnant or breastfeeding, and it is safe for you to receive radiation therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a combination of radiation therapy, lenalidomide, and glofitamab for people with a type of lymphoma called DLBCL that has not responded to or has returned after initial treatment. The goal is to see if this combination can help when other treatments have failed.
This study tests a “mini-CHOP-like” chemotherapy plan for newly diagnosed diffuse large B-cell lymphoma (DLBCL) in people age 70 and older. It may help you learn whether this gentler regimen works well and is safe in older adults who are newly starting treatment.
This trial tests a new two-step treatment: first a small dose of radiation (131I-Apamistamab) followed by specially designed immune cells (CAR-T cells) to fight your lymphoma. It is for people with DLBCL that has relapsed or not responded to standard therapy.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.